312 related articles for article (PubMed ID: 24175678)
1. Biomarkers in IgA nephropathy: relationship to pathogenetic hits.
Hastings MC; Moldoveanu Z; Suzuki H; Berthoux F; Julian BA; Sanders JT; Renfrow MB; Novak J; Wyatt RJ
Expert Opin Med Diagn; 2013 Nov; 7(6):615-27. PubMed ID: 24175678
[TBL] [Abstract][Full Text] [Related]
2. Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy.
Placzek WJ; Yanagawa H; Makita Y; Renfrow MB; Julian BA; Rizk DV; Suzuki Y; Novak J; Suzuki H
PLoS One; 2018; 13(1):e0190967. PubMed ID: 29324897
[TBL] [Abstract][Full Text] [Related]
3. Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression.
Maixnerova D; Ling C; Hall S; Reily C; Brown R; Neprasova M; Suchanek M; Honsova E; Zima T; Novak J; Tesar V
PLoS One; 2019; 14(2):e0212254. PubMed ID: 30794576
[TBL] [Abstract][Full Text] [Related]
4. Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy.
Yasutake J; Suzuki Y; Suzuki H; Hiura N; Yanagawa H; Makita Y; Kaneko E; Tomino Y
Nephrol Dial Transplant; 2015 Aug; 30(8):1315-21. PubMed ID: 26109484
[TBL] [Abstract][Full Text] [Related]
5. Experimental evidence of pathogenic role of IgG autoantibodies in IgA nephropathy.
Moldoveanu Z; Suzuki H; Reily C; Satake K; Novak L; Xu N; Huang ZQ; Knoppova B; Khan A; Hall S; Yanagawa H; Brown R; Winstead CJ; O'Quinn DB; Weinmann A; Gharavi AG; Kiryluk K; Julian BA; Weaver CT; Suzuki Y; Novak J
J Autoimmun; 2021 Mar; 118():102593. PubMed ID: 33508637
[TBL] [Abstract][Full Text] [Related]
6. Significance of serum galactose deficient IgA1 as a potential biomarker for IgA nephropathy: A case control study.
Bagchi S; Lingaiah R; Mani K; Barwad A; Singh G; Balooni V; Bhowmik D; Agarwal SK
PLoS One; 2019; 14(3):e0214256. PubMed ID: 30917188
[TBL] [Abstract][Full Text] [Related]
7. A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases.
Yanagawa H; Suzuki H; Suzuki Y; Kiryluk K; Gharavi AG; Matsuoka K; Makita Y; Julian BA; Novak J; Tomino Y
PLoS One; 2014; 9(5):e98081. PubMed ID: 24858067
[TBL] [Abstract][Full Text] [Related]
8. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy.
Berthoux F; Suzuki H; Thibaudin L; Yanagawa H; Maillard N; Mariat C; Tomino Y; Julian BA; Novak J
J Am Soc Nephrol; 2012 Sep; 23(9):1579-87. PubMed ID: 22904352
[TBL] [Abstract][Full Text] [Related]
9. Serum and urine galactose deficient-IgA1 as alternative biomarkers in the management of IgA nephropathy.
Suleman AA; Abd Ghani F; Fadhlina NZ; Rafidah H
Med J Malaysia; 2024 Jan; 79(1):95-101. PubMed ID: 38287764
[TBL] [Abstract][Full Text] [Related]
10. Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy.
Camilla R; Suzuki H; Daprà V; Loiacono E; Peruzzi L; Amore A; Ghiggeri GM; Mazzucco G; Scolari F; Gharavi AG; Appel GB; Troyanov S; Novak J; Julian BA; Coppo R
Clin J Am Soc Nephrol; 2011 Aug; 6(8):1903-11. PubMed ID: 21784819
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy.
Wada Y; Matsumoto K; Suzuki T; Saito T; Kanazawa N; Tachibana S; Iseri K; Sugiyama M; Iyoda M; Shibata T
PLoS One; 2018; 13(11):e0206865. PubMed ID: 30388165
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis.
Suzuki H
Clin Exp Nephrol; 2019 Jan; 23(1):26-31. PubMed ID: 29740706
[TBL] [Abstract][Full Text] [Related]
13. Galactose-deficient IgA1 in African Americans with IgA nephropathy: serum levels and heritability.
Hastings MC; Moldoveanu Z; Julian BA; Novak J; Sanders JT; McGlothan KR; Gharavi AG; Wyatt RJ
Clin J Am Soc Nephrol; 2010 Nov; 5(11):2069-74. PubMed ID: 20634323
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of Serum Biomarkers of Autoimmunity for Recurrence of IgA Nephropathy after Kidney Transplantation.
Berthoux F; Suzuki H; Mohey H; Maillard N; Mariat C; Novak J; Julian BA
J Am Soc Nephrol; 2017 Jun; 28(6):1943-1950. PubMed ID: 28255003
[TBL] [Abstract][Full Text] [Related]
15. Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy.
Kim MJ; Schaub S; Molyneux K; Koller MT; Stampf S; Barratt J
PLoS One; 2016; 11(12):e0166830. PubMed ID: 27930655
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of galactose-deficient IgA are elevated in patients with IgA nephropathy but do not correlate to disease activity or progression.
Elíasdóttir S; Khramova A; Saeed A; Guron G; Boi R; Mölne J; Ebefors K; Nyström J
BMC Nephrol; 2023 Jun; 24(1):160. PubMed ID: 37286948
[TBL] [Abstract][Full Text] [Related]
17. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels.
Moldoveanu Z; Wyatt RJ; Lee JY; Tomana M; Julian BA; Mestecky J; Huang WQ; Anreddy SR; Hall S; Hastings MC; Lau KK; Cook WJ; Novak J
Kidney Int; 2007 Jun; 71(11):1148-54. PubMed ID: 17342176
[TBL] [Abstract][Full Text] [Related]
18. Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes.
Berthelot L; Robert T; Vuiblet V; Tabary T; Braconnier A; Dramé M; Toupance O; Rieu P; Monteiro RC; Touré F
Kidney Int; 2015 Oct; 88(4):815-22. PubMed ID: 26061544
[TBL] [Abstract][Full Text] [Related]
19. A cross-sectional analysis of clinicopathologic similarities and differences between Henoch-Schönlein purpura nephritis and IgA nephropathy.
Sugiyama M; Wada Y; Kanazawa N; Tachibana S; Suzuki T; Matsumoto K; Iyoda M; Honda H; Shibata T
PLoS One; 2020; 15(4):e0232194. PubMed ID: 32324811
[TBL] [Abstract][Full Text] [Related]
20. Association of IgG co-deposition with serum levels of galactose-deficient IgA1 in pediatric IgA nephropathy.
Eison TM; Hastings MC; Moldoveanu Z; Sanders JT; Gaber L; Walker PD; Lau KK; Julian BA; Novak J; Wyatt RJ
Clin Nephrol; 2012 Dec; 78(6):465-9. PubMed ID: 23006340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
